Get started
Author

David T. Melnekoff

Observed names: D Melnekoff, D. Melnekoff, David Melnekoff, Melnekoff, David, david Melnekoff
ORCID: 0000-0003-2349-1917
Observed ORCID: 0000-0003-2349-1917
OpenAlex ID: A5069157698
A new method for vitrifying samples for cryoEM
2016 · Ivan Razinkov, Venkata P. Dandey, et al. · Journal of Structural Biology · 136
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
2022 · Oliver Van Oekelen, Karthik Nath, et al. · Blood · 105
PDF
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
2019 · Deepak Perumal, Naoko Imai, et al. · Clinical Cancer Research · 90
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
2021 · Sherry Bhalla, David T. Melnekoff, et al. · Science Advances · 73
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
2017 · A Laganà, D Perumal, et al. · Leukemia · 68
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
2022 · Tarek H. Mouhieddine, Oliver Van Oekelen, et al. · Blood Advances · 43
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
2018 · Alessandro Laganà, Itai Beno, et al. · JCO Precision Oncology · 38
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
2024 · Santiago Thibaud, Ryan L. Subaran, et al. · Blood Cancer Discovery · 22
PDF
Single-Cell Sequencing Technologies in Precision Oncology
2022 · David T. Melnekoff, Alessandro Laganà · Advances in experimental medicine and biology · 21
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
2024 · Sarah Aminov, Orsi Giricz, et al. · Journal of Clinical Investigation · 19
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
2022 · Paula Restrepo, Sherry Bhalla, et al. · JCO Precision Oncology · 18
PDF
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
2025 · Adolfo Aleman, Oliver Van Oekelen, et al. · New England Journal of Medicine · 17
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
2020 · Oliver Van Oekelen, Samir Parekh, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma
2021 · David T. Melnekoff, Yogita Ghodke-Puranik, et al. · Blood · 15
Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T
2021 · Oliver Van Oekelen, Tarek H. Mouhieddine, et al. · Blood · 11
E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients
2018 · Alessandro Lagana, Seongjee Park, et al. · Blood · 10
Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
2018 · Alessandro Lagana, Dan Fu Ruan, et al. · Blood · 9
BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
2024 · Adolfo Aleman, Rongbao Zhao, et al. · Blood · 8
PDF
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
2022 · Muhammad Elnaggar, Sarita Agte, et al. · Journal of Hematology & Oncology · 8
PDF
Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
2024 · Tarek H. Mouhieddine, Junia Vieira, et al. · Blood · 6
ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes
2020 · Rafail Nikolaos Tasakis, Alessandro Laganà, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Pathogenic Germline Variants in Multiple Myeloma
2021 · Santiago Thibaud, Aaron Etra, et al. · Blood · 5
Patient Similarity Network of Multiple Myeloma Identifies Patient Sub-groups with Distinct Genetic and Clinical Features
2020 · Sherry Bhalla, David T. Melnekoff, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 5
PDF
Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma
2023 · Junia Vieira dos Santos, David Melnekoff, et al. · Blood · 4
Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project
2017 · Alessandro Laganà, David T. Melnekoff, et al. · Blood · 4
Works count: 91
Citation count: 776
H-index: 14
I10-index: 16
Year
Topic
Type